Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$268.46
-2.56-0.94%
At close: -
$266.52
-1.94-0.72%
After Hours: Mar 28, 6:55 PM EDT
Comments
Loading...
Alnylam Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:ALNY | Benzinga
Alnylam Pharmaceuticals Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Alnylam Pharmaceuticals Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
Citigroup
Canaccord Genuity
RBC Capital
Scotiabank
1calculated from analyst ratings
Analyst Ratings for Alnylam Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/24/2025 | Buy Now | — | JP Morgan | Jessica Fye67% | $280 → $328 | Upgrade | Neutral → Overweight | Get Alert |
| 03/21/2025 | Buy Now | — | Citigroup | David Lebovitz65% | $338 → $351 | Maintains | Buy | Get Alert |
| 03/21/2025 | Buy Now | — | Canaccord Genuity | Whitney Ijem46% | $385 → $390 | Maintains | Buy | Get Alert |
| 03/21/2025 | Buy Now | — | RBC Capital | Luca Issi42% | $310 → $330 | Maintains | Outperform | Get Alert |
| 03/21/2025 | Buy Now | — | Scotiabank | Greg Harrison51% | $300 → $338 | Maintains | Sector Outperform | Get Alert |
| 03/21/2025 | Buy Now | — | Wells Fargo | Tiago Fauth42% | $275 → $287 | Maintains | Equal-Weight | Get Alert |
| 03/21/2025 | Buy Now | — | B of A Securities | Tazeen Ahmad55% | $302 → $325 | Maintains | Buy | Get Alert |
| 03/21/2025 | Buy Now | — | Chardan Capital | Keay Nakae58% | $300 → $300 | Maintains | Buy | Get Alert |
| 03/21/2025 | Buy Now | — | Needham | Joseph Stringer51% | $320 → $320 | Reiterates | Buy → Buy | Get Alert |
| 03/11/2025 | Buy Now | — | JP Morgan | Jessica Fye67% | $272 → $280 | Maintains | Neutral | Get Alert |
| 02/26/2025 | Buy Now | — | RBC Capital | Luca Issi42% | $310 → $310 | Reiterates | Outperform → Outperform | Get Alert |
| 02/26/2025 | Buy Now | — | Chardan Capital | Keay Nakae58% | $300 → $300 | Maintains | Buy | Get Alert |
| 02/26/2025 | Buy Now | — | Needham | Joseph Stringer51% | $320 → $320 | Reiterates | Buy → Buy | Get Alert |
| 02/25/2025 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | $400 → $500 | Reiterates | Buy → Buy | Get Alert |
| 02/24/2025 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | $400 → $500 | Maintains | Buy | Get Alert |
| 02/18/2025 | Buy Now | — | Canaccord Genuity | Whitney Ijem46% | $384 → $385 | Maintains | Buy | Get Alert |
| 02/14/2025 | Buy Now | — | Scotiabank | Greg Harrison51% | $310 → $300 | Maintains | Sector Outperform | Get Alert |
| 02/14/2025 | Buy Now | — | Morgan Stanley | Michael Ulz59% | $275 → $284 | Maintains | Equal-Weight | Get Alert |
| 02/14/2025 | Buy Now | — | Needham | Joseph Stringer51% | $320 → $320 | Reiterates | Buy → Buy | Get Alert |
| 02/11/2025 | Buy Now | — | RBC Capital | Luca Issi42% | $300 → $300 | Reiterates | Outperform → Outperform | Get Alert |
| 01/21/2025 | Buy Now | — | RBC Capital | Luca Issi42% | $300 → $300 | Reiterates | Outperform → Outperform | Get Alert |
| 01/13/2025 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | $400 → $400 | Reiterates | Buy → Buy | Get Alert |
| 01/13/2025 | Buy Now | — | Needham | Joseph Stringer51% | $320 → $320 | Reiterates | Buy → Buy | Get Alert |
| 01/07/2025 | Buy Now | — | Bernstein | William Pickering44% | $314 → $310 | Maintains | Outperform | Get Alert |
| 11/18/2024 | Buy Now | — | Piper Sandler | Edward Tenthoff51% | $296 → $296 | Reiterates | Overweight → Overweight | Get Alert |
| 11/18/2024 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | $400 → $400 | Reiterates | Buy → Buy | Get Alert |
| 11/12/2024 | Buy Now | — | Wolfe Research | Andy Chen37% | — | Downgrade | Peer Perform → Underperform | Get Alert |
| 11/04/2024 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | $400 → $400 | Reiterates | Buy → Buy | Get Alert |
| 11/01/2024 | Buy Now | — | Raymond James | Gary Nachman58% | $275 → $298 | Maintains | Outperform | Get Alert |
| 11/01/2024 | Buy Now | — | RBC Capital | Luca Issi42% | $300 → $300 | Reiterates | Outperform → Outperform | Get Alert |
| 11/01/2024 | Buy Now | — | Scotiabank | Greg Harrison51% | $305 → $310 | Maintains | Sector Outperform | Get Alert |
| 11/01/2024 | Buy Now | — | Barclays | Gena Wang50% | $295 → $329 | Maintains | Overweight | Get Alert |
| 11/01/2024 | Buy Now | — | Canaccord Genuity | Whitney Ijem46% | $366 → $384 | Maintains | Buy | Get Alert |
| 11/01/2024 | Buy Now | — | Chardan Capital | Keay Nakae58% | $300 → $300 | Maintains | Buy | Get Alert |
| 11/01/2024 | Buy Now | — | Needham | Joseph Stringer51% | $320 → $320 | Reiterates | Buy → Buy | Get Alert |
| 10/21/2024 | Buy Now | — | TD Cowen | Ritu Baral36% | $282 → $371 | Maintains | Buy | Get Alert |
| 10/18/2024 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | $400 → $400 | Reiterates | Buy → Buy | Get Alert |
| 10/16/2024 | Buy Now | — | Scotiabank | Greg Harrison51% | → $305 | Initiates | → Sector Outperform | Get Alert |
| 10/14/2024 | Buy Now | — | B of A Securities | Tazeen Ahmad55% | $307 → $314 | Maintains | Buy | Get Alert |
| 10/11/2024 | Buy Now | — | Chardan Capital | Keay Nakae58% | $300 → $300 | Maintains | Buy | Get Alert |
| 10/11/2024 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer62% | $220 → $220 | Reiterates | Neutral → Neutral | Get Alert |
| 10/10/2024 | Buy Now | — | RBC Capital | Luca Issi42% | $300 → $300 | Reiterates | Outperform → Outperform | Get Alert |
| 10/10/2024 | Buy Now | — | Needham | Joseph Stringer51% | $320 → $320 | Reiterates | Buy → Buy | Get Alert |
| 09/19/2024 | Buy Now | — | RBC Capital | Luca Issi42% | $300 → $300 | Reiterates | Outperform → Outperform | Get Alert |
| 09/09/2024 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer62% | $220 → $220 | Reiterates | Neutral → Neutral | Get Alert |
| 09/04/2024 | Buy Now | — | RBC Capital | Luca Issi42% | $300 → $300 | Reiterates | Outperform → Outperform | Get Alert |
| 09/04/2024 | Buy Now | — | B of A Securities | Tazeen Ahmad55% | $295 → $307 | Maintains | Buy | Get Alert |
| 08/30/2024 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | $400 → $400 | Reiterates | Buy → Buy | Get Alert |
| 08/26/2024 | Buy Now | — | JP Morgan | Jessica Fye67% | $248 → $280 | Maintains | Neutral | Get Alert |
| 08/20/2024 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | $400 → $400 | Reiterates | Buy → Buy | Get Alert |
| 08/16/2024 | Buy Now | — | Goldman Sachs | Salveen Richter53% | $198 → $370 | Upgrade | Neutral → Buy | Get Alert |
| 08/02/2024 | Buy Now | — | RBC Capital | Luca Issi42% | $265 → $300 | Maintains | Outperform | Get Alert |
| 08/02/2024 | Buy Now | — | Wells Fargo | Tiago Fauth42% | $207 → $233 | Maintains | Equal-Weight | Get Alert |
| 08/02/2024 | Buy Now | — | Raymond James | Gary Nachman58% | $208 → $275 | Maintains | Outperform | Get Alert |
| 08/02/2024 | Buy Now | — | Goldman Sachs | Salveen Richter53% | $174 → $198 | Maintains | Neutral | Get Alert |
| 08/02/2024 | Buy Now | — | Citigroup | David Lebovitz65% | $291 → $342 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | — | Barclays | Gena Wang50% | $291 → $295 | Maintains | Overweight | Get Alert |
| 08/02/2024 | Buy Now | — | Canaccord Genuity | Whitney Ijem46% | $357 → $366 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | — | Needham | Joseph Stringer51% | $275 → $320 | Maintains | Buy | Get Alert |
| 07/22/2024 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer62% | $150 → $220 | Maintains | Neutral | Get Alert |
| 07/12/2024 | Buy Now | — | Morgan Stanley | Michael Ulz59% | $250 → $255 | Maintains | Equal-Weight | Get Alert |
| 07/08/2024 | Buy Now | — | Canaccord Genuity | Whitney Ijem46% | $283 → $357 | Maintains | Buy | Get Alert |
| 07/03/2024 | Buy Now | — | JP Morgan | Jessica Fye67% | $160 → $248 | Maintains | Neutral | Get Alert |
| 07/01/2024 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer62% | $150 → $150 | Reiterates | Neutral → Neutral | Get Alert |
| 06/28/2024 | Buy Now | — | UBS | Eliana Merle46% | $253 → $288 | Maintains | Buy | Get Alert |
| 06/27/2024 | Buy Now | — | RBC Capital | Luca Issi42% | $250 → $265 | Maintains | Outperform | Get Alert |
| 06/27/2024 | Buy Now | — | Stifel | Paul Matteis43% | $215 → $295 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | — | Citigroup | David Lebovitz65% | $227 → $291 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | — | B of A Securities | — | $248 → $295 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | — | Leerink Partners | — | $138 → $159 | Maintains | Market Perform | Get Alert |
| 06/25/2024 | Buy Now | — | TD Cowen | Ritu Baral36% | $260 → $282 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | — | Evercore ISI Group | Liisa Bayko70% | $210 → $260 | Maintains | Outperform | Get Alert |
| 06/25/2024 | Buy Now | — | Barclays | Gena Wang50% | $236 → $291 | Maintains | Overweight | Get Alert |
| 06/25/2024 | Buy Now | — | RBC Capital | Luca Issi42% | $235 → $250 | Maintains | Outperform | Get Alert |
| 06/25/2024 | Buy Now | — | Wells Fargo | Tiago Fauth42% | $161 → $207 | Maintains | Equal-Weight | Get Alert |
| 06/25/2024 | Buy Now | — | Morgan Stanley | Michael Ulz59% | $164 → $250 | Maintains | Equal-Weight | Get Alert |
| 06/24/2024 | Buy Now | — | Needham | Joseph Stringer51% | $200 → $275 | Maintains | Buy | Get Alert |
| 06/24/2024 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | $400 → $400 | Reiterates | Buy → Buy | Get Alert |
| 06/24/2024 | Buy Now | — | BMO Capital | Kostas Biliouris34% | $234 → $234 | Maintains | Outperform | Get Alert |
| 06/21/2024 | Buy Now | — | Canaccord Genuity | Whitney Ijem46% | $283 → $283 | Maintains | Buy | Get Alert |
| 05/07/2024 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | $395 → $400 | Maintains | Buy | Get Alert |
| 05/03/2024 | Buy Now | — | Chardan Capital | Keay Nakae58% | $225 → $225 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | — | Needham | Joseph Stringer51% | $200 → $200 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | Buy Now | — | BMO Capital | Kostas Biliouris34% | $234 → $234 | Maintains | Outperform | Get Alert |
| 03/05/2024 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | $395 → $395 | Reiterates | Buy → Buy | Get Alert |
| 02/23/2024 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer62% | $165 → $150 | Maintains | Neutral | Get Alert |
| 02/21/2024 | Buy Now | — | RBC Capital | Luca Issi42% | $235 → $235 | Reiterates | Outperform → Outperform | Get Alert |
| 02/20/2024 | Buy Now | — | RBC Capital | Luca Issi42% | $235 → $235 | Reiterates | Outperform → Outperform | Get Alert |
| 02/20/2024 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer62% | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 02/16/2024 | Buy Now | — | RBC Capital | Luca Issi42% | $235 → $235 | Reiterates | Outperform → Outperform | Get Alert |
| 02/16/2024 | Buy Now | — | Wells Fargo | Tiago Fauth42% | $171 → $161 | Maintains | Equal-Weight | Get Alert |
| 02/16/2024 | Buy Now | — | Citigroup | David Lebovitz65% | $237 → $227 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | — | Chardan Capital | Keay Nakae58% | $250 → $225 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | — | Goldman Sachs | Salveen Richter53% | $230 → $173 | Downgrade | Buy → Neutral | Get Alert |
| 02/15/2024 | Buy Now | — | Needham | Joseph Stringer51% | $200 → $200 | Reiterates | Buy → Buy | Get Alert |
| 02/15/2024 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer62% | $165 → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 02/15/2024 | Buy Now | — | Wolfe Research | Andy Chen37% | — | Initiates | → Peer Perform | Get Alert |
| 02/14/2024 | Buy Now | — | RBC Capital | Luca Issi42% | $235 → $235 | Reiterates | Outperform → Outperform | Get Alert |
| 02/13/2024 | Buy Now | — | Morgan Stanley | Michael Ulz59% | $184 → $176 | Maintains | Equal-Weight | Get Alert |
| 02/12/2024 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer62% | $165 → $165 | Reiterates | Neutral → Neutral | Get Alert |
FAQ
What is the target price for Alnylam Pharmaceuticals (ALNY) stock?
The latest price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) was reported by JP Morgan on March 24, 2025. The analyst firm set a price target for $328.00 expecting ALNY to rise to within 12 months (a possible 23.07% upside). 83 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Alnylam Pharmaceuticals (ALNY)?
The latest analyst rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) was provided by JP Morgan, and Alnylam Pharmaceuticals upgraded their overweight rating.
When was the last upgrade for Alnylam Pharmaceuticals (ALNY)?
The last upgrade for Alnylam Pharmaceuticals Inc happened on March 24, 2025 when JP Morgan raised their price target to $328. JP Morgan previously had a neutral for Alnylam Pharmaceuticals Inc.
When was the last downgrade for Alnylam Pharmaceuticals (ALNY)?
The last downgrade for Alnylam Pharmaceuticals Inc happened on November 12, 2024 when Wolfe Research changed their price target from N/A to N/A for Alnylam Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Alnylam Pharmaceuticals (ALNY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Alnylam Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Alnylam Pharmaceuticals was filed on March 24, 2025 so you should expect the next rating to be made available sometime around March 24, 2026.
Is the Analyst Rating Alnylam Pharmaceuticals (ALNY) correct?
While ratings are subjective and will change, the latest Alnylam Pharmaceuticals (ALNY) rating was a upgraded with a price target of $280.00 to $328.00. The current price Alnylam Pharmaceuticals (ALNY) is trading at is $266.52, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.